RESEARCH ARTICLE


MicroRNA155 Expression in Relation to BDCAF Scored Behçet's Disease in an Egyptian Patients' Sample



Sally S. Hassouna1, *, Manal Y. Tayel1, Dalal M. ElKaffash2, Ahmed M. Abdelhady3, Eman H. Elsayed1
1 Department of Internal Medicine, Faculty of Medicine, Alexandria University, Alexandria, Egypt
2 Department of Clinical and Chemical Pathology, Faculty of Medicine, Alexandria University, Alexandria, Egypt
3 Department of Opthalmology, Faculty of Medicine, Alexandria University, Alexandria, Egypt


Article Metrics

CrossRef Citations:
3
Total Statistics:

Full-Text HTML Views: 3483
Abstract HTML Views: 1623
PDF Downloads: 857
ePub Downloads: 532
Total Views/Downloads: 6495
Unique Statistics:

Full-Text HTML Views: 1392
Abstract HTML Views: 841
PDF Downloads: 503
ePub Downloads: 388
Total Views/Downloads: 3124



Creative Commons License
© 2018 Hassouna et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: (https://creativecommons.org/licenses/by/4.0/legalcode). This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the Department of Internal Medicine, Faculty of Medicine, Alexandria University, Alexandria, Egypt; Tel: 01223433443; E-mails: sallysaadhassouna@gmail.com, s_hassouna151@alexmed.edu.eg


Abstract

Objective:

To discover the possibility of using microRNA155 (miRNA155) expression level as a biomarker of Behçet's Disease (BD) activity or remission.

Methods:

Thirty BD patients’ white blood cells (WBCs) miRNA155 expression was measured and compared to WBCs miRNA155 expression in 15 healthy subjects. Assessment of disease activity was done using Behçet's Disease Current Activity Form (BDCAF).

Results:

miRNA155 expression significantly decreases with the increase of BD activity scored by BDCAF.

Conclusion:

Increased miRNA155 may be used as a biomarker of BD remission and thus in the disease follow up. There could be a prospect of treating the disease via microRNA 155 effect enhancement.

Keywords: Behçet's disease, MicroRNA155, BDCAF, Egyptian patients, miRNA155, CD40.